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Abstract
Background: B-cell dysregulation has been implicated but not fully characterized in pediatric
opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder.
Objective: To assess the role of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two
critical B cell-modulating cytokines, as potential biomarkers of disease activity and treatment biomarkers in OMS.
Methods: Soluble BAFF and APRIL were measured in cerebrospinal fluid (CSF) and serum by ELISA in 433 children
(296 OMS, 109 controls, 28 other inflammatory neurological disorders (OIND)). BAFF-R receptors on circulating CD19
+ B cells were measured by flow cytometry. A blinded scorer rated motor severity on the OMS Evaluation Scale.
Immunotherapies were evaluated cross-sectionally and longitudinally.
Results: The mean CSF BAFF concentration, which was elevated in untreated OMS and OIND, correlated with OMS
severity category (P = 0.006), and reduction by adrenocorticotropic hormone or corticotropin (ACTH) (−61%) or
corticosteroids (−38%) was seen at each level of severity. In contrast, CSF APRIL was normal in OMS and OIND and
unaffected by immunotherapy. When the entire OMS dataset was dichotomized into ‘high’ versus ‘normal’ CSF BAFF
concentration, the phenotype of the high group included greater motor severity and number of CSF oligoclonal
bands, and a higher concentration of inflammatory chemokines CXCL13 and CXCL10 in CSF and CXCL9 and CCL21
in serum. Serum APRIL was 6.7-fold higher in the intravenous immunoglobulins (IVIg) group, whereas serum BAFF
was 2.6-fold higher in the rituximab group. The frequency of B cell BAFF-R expression was similar in untreated and
treated OMS. Longitudinal studies of CSF BAFF revealed a significant decline in ACTH-treated patients (with or
without rituximab) (P < 0.0001). Longitudinal studies of serum APRIL showed a 2.9-fold increase after 1 to 2 g/kg
IVIg monotherapy (P = 0.0003).
Conclusions: Striking distinctions in BAFF/APRIL signaling were found. OMS displayed heterogeneity in CSF BAFF
expression, which met many but not all criteria as a potential biomarker of disease activity. We speculate that CSF
BAFF may have more utility in a biomarker panel than as a stand-alone biomarker, and that the selective
upregulation of both serum APRIL by IVIg and BAFF by rituximab, as well as downregulation of CSF BAFF by ACTH/
steroids, may have utility as treatment biomarkers.
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Introduction
Opsoclonus-myoclonus syndrome (OMS) is a neuroin-
flammatory disorder of children and adults, which is dem-
onstrably paraneoplastic in about 50% of the cases [1].
Our research on CSF in pediatric OMS has shown that B
cells are expanded [2], B cell chemoattractant CXCL13 [3]
and B/T cell chemoattractant CXCL10 [4] are likewise
overexpressed, and 35% of the patients harbor oligoclonal
bands. [5] Responses to current immunotherapeutic strat-
egies, such as intravenous immunoglobulins (IVIg), corti-
costeroids, and anti-CD20, also are consistent with B-cell
involvement [2].
Two critical cytokines for B-cell activation, prolifera-
tion, homeostasis, and survival are a proliferating-
inducing ligand (APRIL) and B-cell activating factor
(BAFF) [6]. They are members 13 and 13B, respectively,
of the tumor necrosis factor ligand superfamily (TNFLS)
[7,8]. Both are expressed by astrocytes [9,10], and also
dendritic cells, macrophages, and monocytes [11]. In
human cerebrospinal fluid (CSF) and serum, they are
found in soluble form and often studied together in neu-
roinflammatory diseases [12-14]. The BAFF receptor
(BAFF-R or BR3), one of three receptors to which BAFF
binds [11], is the principal BAFF receptor [15] expressed
by nearly all mature B cells [10].
Our preliminary work on BAFF showed an increase in
OMS and decrease by corticotropin (ACTH) or corticos-
teroids [16]. The present report in an increased OMS sam-
ple size tests the hypothesis that BAFF is a biomarker of
disease activity and treatment biomarker (not diagnostic
biomarker). It includes additional immunotherapy cross-
sectional groups; analysis of the relation to OMS severity
(video documented and scored) and duration; comparison
with APRIL, inflammatory chemokines, oligoclonal bands,
and lymphocyte subsets; longitudinal studies of BAFF and
APRIL, and comparative studies in other inflammatory
neurological disorders (OIND). To identify the ‘phenotype’
of the patients with high CSF values compared to those
with normal (control-like) values, we are now able to
dichotomize the dataset. We also measured the BAFF-R
receptor on circulating B cells in the current study.
Methods
Patients and procedures
This prospective, case–control, translational research
study is part of the ‘Study of Cytokines in Children with
Opsoclonus-Myoclonus Syndrome’ (ClinicalTrials.gov
NCT 00806182) [3]. Approximately 300 children were
recruited through the National Pediatric Myoclonus
Center, regardless of severity or treatment status. Inclu-
sion criteria included clinically confirmed diagnosis of
OMS and ages 0.6 to 18 years, without restriction due to
gender, race, ethnicity, or socioeconomic status. Exclu-
sion criteria were contraindications to lumbar puncture
or sedation/anesthesia, drug treatments outside the
study scope, or concurrent autoimmune disorders.
The cross-sectional part of the study involved 276 chil-
dren with OMS, mean age (SD) 3.8 ± 3.0 years (range 0.89
to 17 years; boys n = 120; girls n = 156), who were en-
rolled after consent was signed by parents and assent by
older children. OMS groups included untreated, currently
treated, and previously treated patients. Videotapes were
made using a standardized procedure and later scored
blinded on the OMS Evaluation Scale to yield a total score
[2]. Further details of treatment and scoring are provided
in the figure legends. The children underwent a morning
lumbar puncture following our specified protocol [2].
Controls comprised children with various non-inflammatory
neurological disorders (NIND), including ataxia, devel-
opmental disorders, headache, movement disorders, sei-
zures, and miscellaneous disorders. Their mean age was
8.4 ± 5.6 years, and 96 were boys and 91 were girls. Chil-
dren with OIND, who were evaluated locally and through
the Center for Pediatric-Onset Demyelinating Disease in
Alabama, served as a comparison group for specificity.
Their diagnoses included acute disseminated encephalo-
myelitis, encephalitis, meningitis, multiple sclerosis and
related disorders, and miscellaneous disorders. The
OINDmean age was 7.7 ± 5.8 years (range 0.1 to 18 years;
boys n = 17; girls n =23).
Two longitudinal OMS studies were performed. In the
BAFF study, 42 children from the cross-sectional study
were treated using ACTH-based conventional therapy
with (n = 31) or without (n = 11) rituximab. There were
16 boys and 26 girls, mean age 3.7 ± 2.8 years (range 1.8
to 18 years). CSF was obtained before and at 8.0 ± 2.1
months of treatment. In the APRIL study, 20 new chil-
dren with OMS were recruited for monotherapy with
intravenous immunoglobulins (IVIg) under FDA BB-
IND No. 5839. There were 11 boys and nine girls, mean
age 4.6 ± 1.4 years (range 1.8 to 6.4 years). They received
standard monthly clinical doses of 1 or 2 g/kg, and
serum was collected before and at 4.1 ± 3.9 months
of treatment.
Cytokine/chemokine detection
CSF and serum were collected on ice, aliquotted, and
stored at −80°C in biorepository freezers. Samples were
thawed on the assay day and BAFF and chemokines were
measured using Quantikine ELISA kits per instructions
by the manufacturer (R&D Systems, Inc., Minneapolis,
MN, USA). The comparison chemokine panel included
CXCL9, CXCL10, CXCL12, CXCL13, CCL17, CCL21,
and CCL22 kits from the same vendor. Human APRIL
ELISA kits were purchased from eBioscience (formerly
Bender MedSystems, Vienna, Austria). Assays were
performed in duplicate on undiluted samples, each
96-well plate containing both control and OMS samples.
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Samples with values above the highest standard were re-
run at a 1:2 or higher dilution. Outliers were verified by
repeat measurement. The kit user had no patient contact.
BAFF sensitivity was 0.73 ± 6.7 pg/mL in CSF, and 1.5 to
11.9 pg/mL in serum; APRIL, 0.4 pg/mL. The inter-assay
coefficient of variance (CV) was 9.4% (n = 22) for CSF
BAFF, 8.5% (n = 20) for serum BAFF, 7.8% (n = 10) for
CSF APRIL, and 4.8% (n = 8) for serum APRIL. The corre-
sponding intra-assay CV was 4.8% (n = 11), 6.0% (n = 10),
7.2% (n = 6), and 6.7% (n = 6). Freezer storage time
and the concentration of CSF BAFF (P = 0.21) or APRIL
(P = 0.16), or serum concentrations, were not correlated.
BAFF-R and lymphocyte subsets
BAFF-R receptors were measured ex vivo by flow cyto-
metry [17]. Peripheral venous blood was delivered to the
flow cytometrist within 1 h of collection. A 100 μL ali-
quot was blocked with 0.2 mg/mL normal mouse IgG
for 15 min at room temperature. Directly conjugated
monoclonal antibody probes (anti-BAFF-R, anti-CD19,
anti-CD45), purchased from Becton Dickinson (San Jose,
CA, USA), were added to the remaining cell suspension.
Then 2 mL FACS lysing solution was added to lyse ery-
throcytes, followed by a 10-min incubation at room
temperature in the dark. The assay suspension was cen-
trifuged at 4°C for 7 min at 600 × g, supernatant was
removed, the pellet was washed twice with 2 mL cold
FACS buffer, and recentrifuged. After decanting, 100 μL of
1% paraformaldehyde was added, and after 5 min at room
temperature in the dark, there was another centrifugation,
decanting, and resuspension of cells in FACS buffer.
Lymphocyte subsets, measured by flow cytometry as
described previously [2], included cells that were CD19
+CD3- (B cells), CD4+CD3+ (T helper/inducer cells),
CD8+CD3+ (T cytotoxic/suppressor cells), TCRγδ+
(gamma/delta T cells), or CD16/56+ (NK cells). Data were
acquired on a FACSCalibur cytometer and analyzed using
Cell Quest (Becton-Dickinson, San Jose, CA, USA). Qual-
ity control measures were rigorous, as reported elsewhere
[2]. The flow cytometrist had no patient contact.
Statistical analysis
Because of inter-individual differences and the large range
of values inherent in human cytokine and chemokine data,
both means and medians were analyzed. Cross-sectional
groups were compared by analysis of variance (ANOVA)
with Tukey post-hoc tests, and primary comparisons were
between controls and untreated OMS, and between un-
treated and treated OMS. Medians were analyzed secondar-
ily by the Kruskal-Wallis test with Dunn’s post-hoc test.
Two group comparisons were made by two-tailed t tests or
Mann–Whitney tests, depending on variance, but pre- and
post-treatment comparisons utilized the paired t test. Per-
centages were compared by Fisher’s exact test. Correlation
analysis utilized Pearson correlations. Although the mean
age of the OMS group was significantly lower than in con-
trols or the OIND group (which did not differ), no correl-
ation between age of controls and CSF BAFF
concentration (P = 0.72) or CSF APRIL (P = 0.19) was
found, and the age range of the groups was equivalent.
Secondary analysis was performed on the OIND group
compared to the other groups. Also, OMS immunother-
apy groups were bundled based on common treatment
effects for graphic presentation. Lastly, the dataset was
dichotomized based on cytokine levels 2 SD above the
control mean to determine if two different phenotypes
emerged, and family-wise Bonferroni corrections (α at
0.5/n) were performed separately on six clinical variables
(P < 0.008), nine chemokines/cytokines and oligoclonal
bands (P < 0.0055), and five lymphocyte subsets




Differences in CSF BAFF were highly significant between
groups (Figure 1A). Mean CSF BAFF was 57% higher in
untreated OMS than in controls. Twenty-three percent
of untreated OMS had CSF BAFF concentrations >2 SD
above the control mean. The three ACTH groups are
shown bundled, as are the three steroid groups, for lack
of significant difference in CSF BAFF among them. CSF
BAFF was 56% lower in ‘All ACTH Groups’ and 45%
lower in ‘All Steroid Groups.’
In comparisons of individual OMS treatment groups ver-
sus untreated OMS (data not shown), significantly lower
mean CSF BAFF concentrations (pg/mL) were found for
ACTH (88 ± 59, -61%, P < 0.0001), steroid (140 ± 148,
-38%, P = 0.002), ACTH + IVIg (113 ± 92, -50%,
P < 0.0001), steroid + IVIg (114 ± 42, -49%, P = 0.0002),
ACTH + other (89 ± 76, -60%, P < 0.0001), and steroid +
other (115 ± 52, -49%, P = 0.005). In each of those groups,
the mean BAFF concentration was below, though not
significantly different than, the control mean. Of actively
treated patients, 22% had CSF BAFF concentrations
below the lowest controls. In previously treated patients,
mean CSF BAFF concentration did not differ significantly
from controls.
The OIND group also manifested an elevated mean
CSF BAFF concentration compared to untreated OMS
(P = 0.04) and controls (P < 0.0001), though there was no
significant difference in medians. In four OIND, whose
diagnoses included encephalitis, neurolupus, and develop-
mental delay, the CSF BAFF concentration was above the
highest control in the 369 to 1,398 pg/mL range. The CSF:
serum BAFF ratios did not differ between these groups.
ACTH and steroid monotherapy groups did not differ
significantly in CSF BAFF concentrations (P = 0.06,
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t-test and Mann–Whitney test). When all ACTH groups
(n = 90) were compared to all steroid groups (n = 62),
there was no significant difference in CSF BAFF concen-
trations: 91 ± 78 vs 123 ± 95 pg/mL, respectively. Only
the combined ACTH group was significantly lower than
the IVIg group (184 ± 136 pg/mL).
The mean CSF/serum BAFF ratio was 64% higher in un-
treated OMS than in controls (P < 0.0001). Compared to
untreated OMS, there were significant ratio reductions in
treated groups. The lowest ratios were for ACTH (0.11 ±
0.06, -55%, P = 0.0007), steroids (0.12 ± 0.05, -49%,
P = 0.02), ACTH + IVIg (0.14 ± 0.10, -38%, P = 0.02), ster-
oid + IVIg (0.15 ± 0.06, -49%, P = 0.008), ACTH + other
treatments (0.07 ± 0.05, -70%, P = 0.009), and steroid +
other treatments (0.08 ± 0.05, -63%, P = 0.02).
The mean serum BAFF concentration did not reflect
CSF concentrations (Figure 1B). It was significantly higher
only in rituximab-treated patients receiving combination
immunotherapy. The BAFF elevation was two-fold in the
ACTH + other group and 2.3-fold in the steroid + other
group. When the ACTH + other and steroid + other
groups were combined, the 50% treated with rituximab
had a 2.6-fold higher serum BAFF (3,186 ± 1,774 pg/mL)
than the rest treated with chemotherapy or steroid sparers
(1,236 ± 779 pg/mL) (P < 0.0001).
APRIL cross-sectional study
The CSF concentration of APRIL did not differ signifi-
cantly between the control group and OMS cross-sectional
groups (Figure 2A). Neither ACTH nor steroids lowered
the concentration of CSF APRIL, and IVIg also had no ef-
fect. CSF APRIL was not elevated in the OIND group.
Combined IVIg treatment groups displayed signifi-
cantly higher serum APRIL concentrations (Figure 2B);
so did individual IVIg groups (see figure legend). In con-
trast, serum APRIL in ACTH- or steroid-treated groups
did not differ from untreated OMS or controls, which
did not differ from each other. The APRIL concentration
in serum did not reflect that in CSF.
As a result of increased serum APRIL, the CSF:serum
APRIL ratio was lower by 53% in the IVIg monotherapy
group, 60% in the ACTH + IVIg group, and 81% in the
steroid + IVIg group compared to untreated OMS. In
controls, the CSF:serum APRIL ratio was 5.8-fold higher
than the CSF:serum BAFF ratio (P < 0.0001); in
untreated OMS, it was 2.8-fold higher (P < 0.0001).
Relation to clinical data
Patients were separated according to OMS severity or
duration. Mean CSF BAFF concentration increased sig-
nificantly with OMS severity category in the combined
OMS dataset (n = 271) (P = 0.006, ANOVA); so did the
median (P = 0.02, Kruskal-Wallis test). For OMS dur-
ation category, there was no significant relation to CSF
BAFF (P = 0.11). The CSF:serum BAFF ratio correlated
with OMS total score (r = 0.38, P = 0.018), OMS dur-
ation (r = −0.48, P = 0.0018), and CSF B cell frequency
(r = 0.59, P = 0.0087). When all groups receiving either
ACTH or steroids were analyzed separately from all
remaining OMS groups, they manifested the lowest CSF
BAFF concentrations regardless of OMS severity
(Figure 3A) or duration category (Figure 3B). Only in
the remaining OMS groups did CSF BAFF concentration
trend with OMS severity and OMS duration.
For serum APRIL, there were no significant differences
between severity or duration categories when the entire
OMS dataset was used (P = 0.27). However, when the
Figure 1 Cross-sectional BAFF concentrations. (A) CSF BAFF. Box
and whisker graphs depict the mean as a plus sign, the median as a
line within the box, interquartile ranges as the upper and lower box
lines, and the range as Tukey error bars. Primary statistical
comparisons were of means for untreated OMS versus controls (*)
and treated versus untreated OMS (†). Statistical significance level is
indicated by the number of symbols: * 0.05 > P ≥0.01, *** P ≤0.0001.
The pre-bundled treatment groups were ACTH (n = 37), steroids (n =
22), IVIG (n = 24), ACTH + IVIg (n = 39), steroids + IVIg (n = 27),
ACTH + other (rituximab, chemotherapy, or steroid sparers) (n = 14),
and steroids + other (n = 13). None of the three ACTH groups
differed from each other in BAFF concentration, so they were
bundled into ‘All ACTH Groups’. Steroid groups were bundled the
same way. OIND was significantly different than all other groups (‡).
The mean ACTH dose in the combined ACTH groups was 28 ± 22
IU/m2/day (alternate day doses averaged to provide a daily dose
equivalent). The mean steroid dose was 1.3 ± 1.3 mg/kg/day. (B)
Serum BAFF. The ACTH monotherapy group and the ACTH + IVIg
group, which were not significantly different in BAFF concentrations,
were bundled into group 2; steroids were handled likewise in group
3. The ‘Rituximab + Other’ group included rituximab, IVIg, and either
steroids or ACTH.
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OMS dataset was split into no IVIg groups versus all
IVIg groups, significant differences were found for IVIg
at each level of OMS severity (Figure 3C) and for two
categories of OMS duration (Figure 3D). There was no
significant difference across severity categories.
The tumor OMS group (1.14 ± 95 pg/mL, n = 137) and
the non-tumor OMS group (1.11 ± 0.68 pg/mL, n = 130)
did not differ significantly in mean serum BAFF concentra-
tion (P = 0.79), or in medians (P = 0.42). Mean serum
APRIL concentration in the tumor group (30.3 ± 70 ng/mL)
and non-tumor group (19.7 ± 30 ng/mL) also was not sig-
nificantly different (P = 0.22).
The OMS combined dataset was analyzed for various cor-
relations. CSF BAFF, not APRIL, correlated with CSF
leukocyte count (P = 0.0003, Pearson correlation), though
the r value was low (r = 0.24). There were no significant cor-
relations with CSF IgG concentration or the albumin ratio.
Secondary analysis
The whole OMS dataset was divided into two groups as
described under statistical analysis (Figure 4). In the
resulting ‘high’ BAFF group (n = 23), there was a signifi-
cantly higher concentration of CSF CXCL13 and CXCL10,
CSF oligoclonal band number and frequency, and serum
CXCL9 and CCL21 compared to the ‘normal’ BAFF group
(n = 253). The clinical characteristics of this group were
greater total score (motor severity) and a higher frequency
of untreated patients. CSF T cell frequency was lower in
the ‘high’ BAFF group (80.3 ± 8.1%) than the ‘normal’
BAFF group (85.2 ± 7.0%) (P = 0.004). There were no sig-
nificant between-group differences after Bonferroni cor-
rections for CSF or serum APRIL, plasma CXCL12, serum
CCL17, serum CCL22, or for CSF lymphocyte subset fre-
quencies (CD19+ B cells, γδ T cells, CD4+ T cells, CD8+
T cells, or NK cells) (data not shown).
Because certain treatments alter CSF BAFF concentra-
tions, the analysis was then performed only for untreated
OMS, for which there were 10 ‘high’ and 34 ‘normal,’
with non-significant trends: CSF CXCL13 (P = 0.06),
serum CXCL9 (P = 0.08). When the sample was
increased by inclusion of all non-ACTH/steroid groups,
there were 10 ‘high’ and 106 ‘normal’. The statistically
significant results were for CSF CXCL13 (P = 0.01), CSF
OCB frequency (P = 0.04) and number (P = 0.03), serum
CXCL9 (P = 0.02), and total score (P = 0.02); CXCL10
and CCL21 were not significant. Thus, the ‘high’ group
appeared statistically underpowered when the dataset
was delimited.
BAFF-R
BAFF-R was expressed on almost all circulating CD19+ B
cells, whether from controls or OMS. Mean BAFF-R
frequency was 94.5 ± 9.3% for untreated OMS (n = 6),
97.1 ± 5.4% for conventionally-treated OMS (n = 9), 90.1 ±
12.2% for multimodal immunotherapy (n = 13), and 96.9 ±
2.2% in controls, with no significant differences between
groups (P = 0.45). Median frequencies also did not differ
significantly (P = 0.62, Kruskal-Wallis test).
Longitudinal CSF BAFF study
The mean CSF BAFF concentration in pre-treatment
OMS was higher than in controls (P < 0.0001). It declined
significantly in children receiving ACTH-based immuno-
therapy (Figure 4A), whether or not they also received
rituximab (Figure 4B,C). Of the 42 patients, BAFF
decreased in 36, did not change in two, and increased in
four. The only distinguishing characteristic of patients
showing a BAFF decrease was lower CSF CXCL13 (2.6
pg/mL) than the others (4.1 pg/mL) (P = 0.02). Post-
treatment CSF BAFF concentration was in the normal
range. Although there was an overall 71% reduction in
motor severity (total score) (P < 0.0001), the change in
BAFF did not correlate with the change in total score,
even when patients without a decrease in BAFF were
excluded (r = 0.19, P = 0.29).
Figure 2 Cross-sectional APRIL concentrations. (A) CSF APRIL,
expressed as ng/mL (1000 × pg/mL). The pre-bundled treatment
groups were ACTH (n = 33), steroids (n = 11), IVIg (n = 14), ACTH +
IVIg (n = 29), steroids + IVIg (n = 14). (B) Serum APRIL, expressed as
ng/mL. The three IVIg groups (IVIg, ACTH + IVIg, steroids + IVIg) did
not differ significantly from each other in serum APRIL
concentration, so they were combined into ‘All IVIg groups’.
Compared to controls, the serum APRIL concentration was higher by
6.7-fold in the IVIg monotherapy group (32.6 ± 34 ng/mL), by 8.2-
fold in the ACTH + IVIg group (39.9 ± 45 ng/mL), and by 6.9-fold in
the steroid + other group (33.3 ± 26 ng/mL). IVIg was infused
monthly, and most evaluations were scheduled just before the next
IVIg was due.
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Longitudinal serum APRIL study
The post-IVIg serum APRIL concentration (Figure 5D)
was significantly higher than the pre-treatment concentra-
tion (mean by 2.8-fold, median by 2.6-fold). Serum APRIL
was increased in all patients, though the amount of
change varied greatly between patients. In six patients, the
post-IVIg APRIL concentration was >1 SD above the con-
trol mean; in four, >2 SD. The increase was significant in
children who received 2 g/kg (Figure 5F), but the sample
size was small in the 1 g/kg group (Figure 5E).
A C
B D
Figure 3 CSF BAFF and serum APRIL concentration versus OMS severity and duration category. (A) Dot plot comparison of BAFF versus
OMS severity in all ACTH/steroid groups versus all other OMS groups. Asterisk denotes P < 0.05 by two-tailed t tests within categories. Severity
categories were pre-defined based on total score as mild (0–12), moderate (13–24), or severe (25–36). Between-category comparisons were made
by ANOVA and Kruskal-Wallis tests. (B) Comparison of BAFF versus OMS duration in all ACTH/steroid groups versus all other OMS groups. OMS
duration was pre-defined as acute (0 to 3 months), subacute (>3 months to 1 year), or chronic (>1 year). (C) Serum APRIL concentrations versus
OMS severity in all IVIg groups versus all non-IVIg groups. (D) Serum APRIL versus OMS duration in all IVIg groups versus all non-IVIg groups.
Figure 4 Dichotomization of CSF BAFF concentration into ‘high’ and ‘normal’ groups for phenotyping. Percentages were compared by
Fisher’s exact tests and means by t tests. The high and normal groups did not differ significantly in gender ratio, patient age, or OMS duration
(data not shown).
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Discussion
This study provides new insights on the BAFF/APRIL
system in pediatric OMS. Correlation of CSF BAFF with
clinical severity and co-segregation of high CSF BAFF
with CSF inflammatory chemokines and oligoclonal
bands suggest a potential role of CSF BAFF as one of
several biomarkers of disease activity in OMS. BAFF also
showed promise as a treatment biomarker in its remark-
able sensitivity to ACTH or corticosteroids in cross-
sectional as well as longitudinal studies. APRIL was not
a biomarker of disease activity in OMS, but showed a
striking treatment effect of IVIg. BAFF-R expression on
circulating B cells was not altered in OMS, nor is it in
multiple sclerosis [10] or myasthenia gravis [18].
The fact that CSF BAFF and APRIL did not trend
in the same direction in OMS is not without prece-
dent [12]. Although both are increased in neuropsychi-
atric lupus [12,14], only CSF BAFF is increased in
untreated multiple sclerosis [19,20]. Another difference
between BAFF and APRIL signaling in neuroinflamma-
tory diseases is that both CSF and serum BAFF are
elevated in neuro-Behcet’s disease [13], whereas only
CSF BAFF is elevated in multiple sclerosis. The highest
CSF BAFF concentrations in multiple sclerosis were
found in patients with more than six oligoclonal bands
[21], which is similar to the higher band counts we
found in OMS. Serum BAFF and APRIL have not
reflected CSF levels in other disorders [9,13,19] or in
the present study.
Differences in APRIL and BAFF responses also may
reflect differences in their functions [11]. Both BAFF
and APRIL bind to BCMA and TACI receptors, how-
ever, only BAFF binds to BAFF-R, and APRIL also
binds to surface proteoglycans [21]. The expression of
these receptors differs on pre-immune B cells and
antigen-experienced B cells (memory B cells and long-
lived plasma cells) [22]. BAFF and APRIL may localize
to different anatomic niches, with distinctive local
interactions. APRIL modulates certain aspects of B cell
activation and isotype switching [22]. Also, BAFF plays
a role in T cell activation and polarization to Th1
[11,15], and APRIL suppresses Th2 cytokine production
and antibody responses in vitro [23].
Extraordinary differential effects of immunotherapy
were found for APRIL and BAFF. To our knowledge,
increased serum APRIL concentration as an effect of
IVIg therapy has not been reported previously in a
neurological disorder. The only previous report we
encountered was of 11 children with Kawasaki disease,
an acute vasculitis that responds to IVIg [24], in whom
an IVIg dose of 2 g/kg raised APRIL (6.7-fold) but low-
ered BAFF (−41%) in plasma. In OMS, we found no
IVIg-lowering effect on serum BAFF. Serum BAFF
increased only after rituximab therapy, which we showed
Figure 5 Longitudinal effects of immunotherapy on CSF BAFF and serum APRIL. (A) CSF BAFF pre- and post-treatment with ACTH-based
combination immunotherapy. Group means with SEM and percent reduction are shown to either side of the line plot. (B) ACTH-based
immunotherapy without rituximab. Comparisons were made by paired t tests. (C) ACTH-based immunotherapy with rituximab. Pre-treatment
means in Figures B and C did not differ significantly; neither did post-treatment means. (D) Pre- and post-IVIg treatment serum APRIL. (E) Data
from 1 g/kg IVIg dose. (F) Data from 2 g/kg IVIg dose. No significant differences were found between pre-treatment means or between post-
treatment means in Figures E and F.
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to be an early response to B cell depletion in OMS [25].
Only ACTH and corticosteroids lowered CSF BAFF, but
they did not affect CSF APRIL. Previously, a reduced
concentration of serum BAFF has been reported in dis-
orders with elevated BAFF, such as in Wegener’s granu-
lomatosis [26]. These differences might be clinically
exploited should they be found to serve as response pre-
dictive biomarkers (identifying subpopulation according
to response potential) or response identification (relating
biological and clinical responses to treatment) biomar-
kers in longitudinal studies.
The clinical impact of IVIg-induced elevation in serum
APRIL is difficult to predict from observational data. In
diseases associated with increased APRIL in serum,
APRIL is thought to have a pathologic role. However,
IVIg induces clinical improvement in OMS [1], and
APRIL is not elevated in untreated OMS, raising the
possibility that boosting serum APRIL could be thera-
peutic in OMS. Interestingly, APRIL has been suggested
to be involved in downregulation of serological and clin-
ical activity in patients with systemic lupus erythemato-
sus [27]. This view is consistent with the proposed mode
of IVIg action, which is thought to be immunomodula-
tion of the cytokine network [28]. However, modulation
of APRIL may not be the mechanism involved.
Treatment-induced reduction of BAFF in the central
nervous system might decrease BAFF-dependent sur-
vival of plasma cells [9], which express BAFF-R [29]. In
pediatric OMS, elevated CSF BAFF (not APRIL) corre-
lated with CSF cerebellar autoantibodies [30], though
the effect of treatment was not studied. Increased serum
BAFF after rituximab, which may be important to B-cell
repopulation [31], could also increase survival of auto-
reactive circulating B cells [29].
BAFF adds to the evolving picture of B-cell involve-
ment in OMS, which includes CSF B-cell subset expan-
sion [2], positive oligoclonal bands [5], intrathecal over-
production of CXCL13 [3], selective over-expression of
CXCR5 receptors on CSF memory B cells [3], and clin-
ical response to adjunctive anti-CD20 monoclonal anti-
body rituximab [1]. One potential limitation of CSF
BAFF as a biomarker is its inter-individual variability.
Moreover, only 23% of patients with untreated OMS had
CSF BAFF concentration >2 SD above the control mean.
This shows significant overlap of CSF BAFF values be-
tween patients and controls. Our current research
explores the hypothesis that inflammatory cytokines,
none of which is elevated in all patients, may have
greater predictive value in OMS as a biomarker cluster
than individually.
In conclusion, BAFF, not APRIL, joins a short list of
other putative CSF biomarkers of disease activity in
pediatric OMS that includes B cell frequency (total B
cells and B-cell subsets), B-cell chemoattractants
(CXCL10, CXCL13), and oligoclonal bands [2-5]. Such
molecules necessary for B-cell recruitment, activation,
and survival may be working together to promote neu-
roinflammation [20]. Because of the exceptional sensi-
tivity of CSF BAFF to peripherally administered ACTH
or corticosteroid therapy, its potential utility as a re-
sponse predictive biomarker or response identification
biomarker warrants validation. The immunomodulatory
effect of IVIg on APRIL signaling merits evaluation in a
variety of neuroinflammatory disorders.
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